Sign In
Buy EVLO
$0.0001
+0 (+0%)
At Close: Jun 22, 2026
Evelo Biosciences Reports Second Quarter 2020 Financial Results and Business Highlights
11:00am, Thursday, 30'th Jul 2020
– FDA authorization of IND for Phase 2 trial of EDP1815 in COVID-19 in the U.S.; data expected in 4Q 2020 – –Achieved regulatory and ethics authorization for Phase 2 dose ranging trial for EDP1
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Annexon...
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
12:00am, Sunday, 26'th Jul 2020
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
Evelo Biosciences to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020
11:00am, Thursday, 23'rd Jul 2020
CAMBRIDGE, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
12:00pm, Tuesday, 07'th Jul 2020
Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™,
CAMBRIDGE, Mass., July 01, 2020 -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically.
The
Evelo Biosciences Announces Pricing of Public Offering of Common Stock
11:56pm, Wednesday, 24'th Jun 2020
Evelo also granted the underwriters a 30-day option, solely to cover over-allotments, if any, to purchase up to an additional 1,800,000 shares of its common stock. All of the shares in the offering a
Evelo Biosciences Announces Proposed Public Offering of Common Stock
08:01pm, Wednesday, 24'th Jun 2020
Evelo expects to grant the underwriters a 30-day option, solely to cover over-allotments, if any, to purchase up to an additional $6 million of its common stock. All of the shares in the proposed off
Evelo Trial Progress, And Other News: The Good, Bad And Ugly Of Biopharma
02:18am, Wednesday, 24'th Jun 2020
Evelo Biosciences proceeds with midstage trial of EDP1815. HOOKIPA reports positive data for HB-101. Theratechnologies reports positive data.
Evelo Biosciences (EVLO) Investor Presentation - Slideshow
04:14pm, Tuesday, 23'rd Jun 2020
The following slide deck was published by Evelo Biosciences, Inc. in conjunction with this event.
Evelo Biosciences Announces EDP1815 to Advance into Phase 2/3 TACTIC-E COVID-19 Trial
06:00am, Monday, 22'nd Jun 2020
Evelo Biosciences, Inc. (EVLO) a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologic therapies, announced today that EDP1815 will be includ
Dublin, June 22, 2020 (GLOBE NEWSWIRE) -- The "US Renal Cell Carcinoma Market and Competitive Landscape - 2020" report has been added to ...
United States Renal Cell Carcinoma Market and Competitive Landscape 2016-2025 - ResearchAndMarkets.com
12:00am, Wednesday, 17'th Jun 2020
The
